Scorching hot healthcare IPOs net HK$2.7bn
Mainland-based firms OcuMension Therapeutics and Immunotech Biopharm sealed their Hong Kong IPOs at the top of guidance, riding on support from both institutional and retail investors.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: